Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Selinexor + etoposide + dexamethasone for critically ill hemophagocytic syndrome (single-arm)
ChiCTR2500096507Phase 4Not yet recruiting
- Sponsor
- First Affiliated Hospital of Soochow University
- Start
- Jan 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of selinexor in haemophagocytic lymphohistiocytosis (HLH), sponsored by First Affiliated Hospital of Soochow University. Primary endpoint: objective response rate. Planned start Jan 2025; status: not yet recruiting.
02
Drugs
selinexor
03
Conditions
haemophagocytic lymphohistiocytosis (HLH)
Beyond the preview
Go deeper on ChiCTR2500096507.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500096507.